Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > 6 Fold Dilution To Chase After COVID-19. End Of Story.

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jul 06, 2021 7:37pm

111 Views

Post# 33503414

RE:RE:RE:RE:RE:RE:RE:6 Fold Dilution To Chase After COVID-19. End Of Story.

Oh no Algernon, I mean Bithorse, I mean BlaineBorg what will I do without you?

to that point, I promised at .30 that when this went to .12 I would leav this board, all the best.

Good Day

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism